Page last updated: 2024-12-08

antalarmin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

antalarmin : A pyrrolopyrimidine that is 7H-pyrrolo[2,3-d]pyrimidin-4-amine which is substituted by methyl groups at positions 2, 5, and 6, by a mesityl group at position 7, and in which the amino substituent at position 4 has been substituted by ethyl and butyl groups. It is an antagonist of corticotropin-releasing factor 1 (CRF-1) receptors (Ki = 1 nM). [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID177990
CHEMBL ID296641
CHEBI ID139557
SCHEMBL ID466243
MeSH IDM0269484

Synonyms (28)

Synonym
7h-pyrrolo(2,3-d)pyrimidin-4-amine, n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-
bdbm50074501
butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-amine(antalarmin)
butyl-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethyl-phenyl)-7h-pyrrolo[2,3-d]pyrimidin-4-yl]-amine
antalarmin
157284-96-3
NCI60_039940
NCGC00165732-01
nsc715590
7h-pyrrolo[2, n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-
nsc-715590
n-butyl-n-ethyl-7-mesityl-2,5,6-trimethyl-7h-pyrrolo[2,3-d]pyrimidin-4-amine
CHEBI:139557
CHEMBL296641 ,
n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[2,3-d]pyrimidin-4-amine
g3dnt7x7yl ,
unii-g3dnt7x7yl
gtpl3489
n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine
SCHEMBL466243
DTXSID50166241
n-butyl-n-ethyl-[2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-7h-pyrrolo[2,3-d]pyrimidin4-yl]-amine
n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)- 7h-pyrrolo[2,3-d]pyrimidin-4-amine
Q4770927
CS-0086611
HY-124475
n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo(2,3-d)pyrimidin-4-amine
7h-pyrrolo[2,3-d]pyrimidin-4-amine, n-butyl-n-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)-

Research Excerpts

Overview

Antalarmin is a pyrrolopyrimidine compound that antagonizes corticotropin-releasing hormone (CRH) type 1 receptors (CRHR1)

ExcerptReferenceRelevance
"Antalarmin (AA) is a specific CRHR-1 antagonist suitable for oral administration."( Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm.
Ayala, AR; Calis, KA; Chrousos, GP; Cizza, G; Gerald, M; Gold, PW; Higley, JD; Lindell, S; Pacak, K; Pushkas, J; Rice, KC; Ronsaville, D, 2004
)
1.04
"Antalarmin is a pyrrolopyrimidine compound that antagonizes corticotropin-releasing hormone (CRH) type 1 receptors (CRHR1). "( Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress.
Bornstein, S; Chrousos, GP; Ehrhart-Bornstein, M; Gold, PW; Licinio, J; Park, CS; Phu, P; Rice, KC; Spokes, H; Webster, EL; Wong, ML, 1999
)
1.98

Effects

ExcerptReferenceRelevance
"Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0."( Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor.
Glaze, E; Jain, P; Karlage, KL; Machatha, SG; Mogalian, E; Myrdal, PB; Narazaki, R; Sanghvi, R; Tabibi, SE; Yalkowsky, SH, 2009
)
1.33
"Antalarmin has a poor water solubility of less than 1 microg/mL and is weakly basic with an experimentally determined pK(a) of 5.0."( Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor.
Glaze, E; Jain, P; Karlage, KL; Machatha, SG; Mogalian, E; Myrdal, PB; Narazaki, R; Sanghvi, R; Tabibi, SE; Yalkowsky, SH, 2009
)
1.33

Actions

Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats. It did, however, allow recovery of body weight in the poststress period.

ExcerptReferenceRelevance
"Antalarmin did, however, allow recovery of body weight in the poststress period."( Antagonism of specific corticotropin-releasing factor receptor subtypes selectively modifies weight loss in restrained rats.
Chotiwat, C; Harris, RB, 2008
)
1.07
"Antalarmin did not produce a place preference or place aversion by itself in morphine-dependent rats."( Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats.
Cador, M; Koob, GF; Stinus, L; Zorrilla, EP, 2005
)
1.05

Treatment

Antalarmin and nadolol-treated mice developed significantly fewer metastatic foci with smaller areas than vehicle-treated subjects. Pretreatment with antalarmine (a selective type-1 CRF receptor antagonist) occludes the CRF-mediated decrease in blood glutamate levels.

ExcerptReferenceRelevance
"Antalarmin treatment was given for 4 and 6 days."( Coping with chronic social stress in mice: hypothalamic-pituitary-adrenal/ sympathetic-adrenal-medullary axis activity, behavioral changes and effects of antalarmin treatment: implications for the study of stress-related psychopathologies.
Arregi, A; Azpiroz, A; Garmendia, L; Gómez-Lázaro, E; Pérez-Tejada, J; Vegas, O, 2013
)
1.31
"Both antalarmin and nadolol-treated mice developed significantly fewer metastatic foci with smaller areas than vehicle-treated subjects although only the group treated with antalarmin had reduced corticosterone levels."( Effects of antalarmin and nadolol on the relationship between social stress and pulmonary metastasis development in male OF1 mice.
Arregi, A; Azpiroz, A; Beitia, G; Garmendia, L; Vegas, O, 2009
)
1.2
"Treatment with antalarmin significantly reduced the size (67% decrease) and number (30% decrease) of endometriotic vesicles."( Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis.
Appleyard, CB; Flores, I; Rivera-Lopez, LL; Torres-Reverón, A, 2018
)
1.06
"Pretreatment with antalarmine (a selective type-1 CRF receptor antagonist) occludes the CRF-mediated decrease in blood glutamate levels."( Regulation of blood L-glutamate levels by stress as a possible brain defense mechanism.
Boyko, M; Dubilet, M; Klin, Y; Kotz, R; Ohayon, S; Shapira, Y; Teichberg, VI; Zlotnik, A, 2010
)
0.68

Pharmacokinetics

ExcerptReferenceRelevance
" On the basis of this property and lipophilicity differences, six of these compounds (4d,i,n,x, 8k, 9a) were initially chosen for rat pharmacokinetic (PK) studies."( Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
Aldrich, PE; Arvanitis, A; Bakthavatchalam, R; Beck, JP; Cheeseman, RS; Chidester, D; Chien, BM; Chorvat, RJ; Cocuzza, AJ; Curry, M; Fernandez, CH; Fitzgerald, LW; Gilligan, PJ; Hobbs, FW; Hodge, CN; Huang, SM; Klaczkiewicz, JD; Krenitsky, P; Rescinito, JP; Shen, HL; Wasserman, ZR; Wilde, RG; Wong, YN; Yarem, JA; Zaczek, R, 1999
)
0.3
"The preformulation, solubilization and pharmacokinetic evaluation of antalarmin, a stress inhibitor, have been conducted."( Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor.
Glaze, E; Jain, P; Karlage, KL; Machatha, SG; Mogalian, E; Myrdal, PB; Narazaki, R; Sanghvi, R; Tabibi, SE; Yalkowsky, SH, 2009
)
0.85

Bioavailability

ExcerptReferenceRelevance
" Pharmacokinetic analysis conducted in rats revealed that the 20% cremophor EL solution formulation has a fivefold higher oral bioavailability compared to a suspension formulation."( Preformulation and pharmacokinetic studies on antalarmin: a novel stress inhibitor.
Glaze, E; Jain, P; Karlage, KL; Machatha, SG; Mogalian, E; Myrdal, PB; Narazaki, R; Sanghvi, R; Tabibi, SE; Yalkowsky, SH, 2009
)
0.61

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetic and dose-response studies suggested that an oral dose of 20 mg/kg was optimal for behavioral and endocrine effects."( Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.
Atkinson, AJ; Champoux, M; Chrousos, GP; Contoreggi, C; Gold, PW; Habib, KE; Higley, JD; Listwak, S; McCann, SM; Pushkas, J; Rice, KC; Schulkin, J; Suomi, SJ; Webster, EL; Weld, KP, 2000
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
corticotropin-releasing factor receptor antagonistA hormone antagonist that blocks corticotropin-releasing factor receptors
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrrolopyrimidine
tertiary amino compoundA compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (6)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency89.12510.004023.8416100.0000AID485290
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency15.21120.00798.23321,122.0200AID2546; AID2551
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Corticotropin-releasing factor receptor 1Homo sapiens (human)IC50 (µMol)0.01860.00070.06490.3400AID1126167; AID1500153
Corticotropin-releasing factor receptor 1Homo sapiens (human)Ki0.00830.00080.01020.2400AID239538; AID239687; AID254614; AID53968; AID638165
Corticotropin-releasing factor receptor 1Rattus norvegicus (Norway rat)Ki0.00100.00100.00290.0050AID53819
Corticotropin-releasing factor receptor 2Rattus norvegicus (Norway rat)Ki0.00100.00100.00150.0020AID53819
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (16)

Processvia Protein(s)Taxonomy
immune responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
cell surface receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
activation of adenylate cyclase activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
female pregnancyCorticotropin-releasing factor receptor 1Homo sapiens (human)
parturitionCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of adenylate cyclase activity involved in G protein-coupled receptor signaling pathwayCorticotropin-releasing factor receptor 1Homo sapiens (human)
adrenal gland developmentCorticotropin-releasing factor receptor 1Homo sapiens (human)
exploration behaviorCorticotropin-releasing factor receptor 1Homo sapiens (human)
fear responseCorticotropin-releasing factor receptor 1Homo sapiens (human)
behavioral response to ethanolCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
general adaptation syndrome, behavioral processCorticotropin-releasing factor receptor 1Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusCorticotropin-releasing factor receptor 1Homo sapiens (human)
negative regulation of voltage-gated calcium channel activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
regulation of corticosterone secretionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (5)

Processvia Protein(s)Taxonomy
protein bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotrophin-releasing factor receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
G protein-coupled peptide receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone bindingCorticotropin-releasing factor receptor 1Homo sapiens (human)
corticotropin-releasing hormone receptor activityCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
endosomeCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
plasma membraneCorticotropin-releasing factor receptor 1Homo sapiens (human)
neuron projectionCorticotropin-releasing factor receptor 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID54138Compound was tested in vitro for its ability to displace [125 I]Tyr-sauvagine from corticotropin-releasing hormone type 1 receptor in rat cerebellum2000Bioorganic & medicinal chemistry letters, Apr-17, Volume: 10, Issue:8
Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor.
AID638165Antagonist activity at human recombinant CRF1 receptor expressed in CHO cells by cAMP assay2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Lead diversification. Application to existing drug molecules: mifepristone 1 and antalarmin 8.
AID53819Compound was tested for the binding affinity to rat corticotropin releasing factor receptor2000Journal of medicinal chemistry, May-04, Volume: 43, Issue:9
Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents.
AID27915Calculated partition coefficient (clogP)2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
AID53982Affinity for the Corticotropin releasing factor receptor 1 (CRHR1) was determined in rat brain2003Journal of medicinal chemistry, Aug-14, Volume: 46, Issue:17
Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.
AID1500153Displacement of [125I]-Tyr0-sauvagine from human CRFR1 expressed in HEK293 cell membrane homogenates after 120 mins by gamma counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Synthesis of 2-imino and 2-hydrazono thiazolo[4,5-d]pyrimidines as corticotropin releasing factor (CRF) antagonists.
AID254614Binding affinity for human corticotropin releasing factor receptor 1 expressed in LtK- cells using [125I]sauvagine2005Journal of medicinal chemistry, Sep-08, Volume: 48, Issue:18
Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
AID239538Inhibition of [125I]sauvagine binding to corticotropin releasing factor receptor 1 expressed in LtK- cells2005Journal of medicinal chemistry, Jun-16, Volume: 48, Issue:12
Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
AID239687Binding affinity for corticotropin-releasing factor-1 expressed in leukocyte tyrosine kinase cells2005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
AID53968Binding affinity to recombinant human Corticotropin releasing factor receptor 1 (hCRF1) expressed in 293EBNA cells1999Journal of medicinal chemistry, Mar-11, Volume: 42, Issue:5
Synthesis, corticotropin-releasing factor receptor binding affinity, and pharmacokinetic properties of triazolo-, imidazo-, and pyrrolopyrimidines and -pyridines.
AID1126167Displacement of [125I]Tyr0sauvagine from human CRF1 receptor expressed in HEK293 cell membrane after 120 mins by gamma scintillation counting analysis2014European journal of medicinal chemistry, May-06, Volume: 78Synthesis of substituted pyrimidines as corticotropin releasing factor (CRF) receptor ligands.
AID1345736Human CRF1 receptor (Corticotropin-releasing factor receptors)1996Endocrinology, Dec, Volume: 137, Issue:12
In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (179)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (4.47)18.2507
2000's86 (48.04)29.6817
2010's80 (44.69)24.3611
2020's5 (2.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.95 (24.57)
Research Supply Index5.20 (2.92)
Research Growth Index5.14 (4.65)
Search Engine Demand Index39.83 (26.88)
Search Engine Supply Index2.05 (0.95)

This Compound (30.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (5.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other171 (94.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]